Results:11 pts have been treated to date; 3 in Group 1, and 8 in...

Results:11 pts have been treated to date; 3 in Group 1, and 8 in Group 2. All pts have received at least 2 cycles of the combination treatment; 2 pts completed 8 cycles, and 2 pts remain on study. Tumour types include lung, prostate, gastric, pancreatic, nasopharyngeal and metastatic squamous carcinoma.

Early signals of tumour response based on RECIST 1.1 criteria include
stable disease in 2 pts (SD at 8 weeks and at 16 weeks);
partial response (PR) in 1 patient at 16 weeks;
complete response (CR) in 2 pts, both with ongoing CR at 24 weeks.
Five pts had disease progression, and
1 pt was withdrawn due to suspected immune mediated myositis and hepatitis resulting from nivolumab and was not evaluable.